{"url_path":"/sec/ngne/8-k/2026-06-29/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1404644/0001404644-26-000046-index.html","accession_number":"0001404644-26-000046","cik":"0001404644","ticker":"NGNE","issuer_name":"Neurogene Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1404644/0001404644-26-000046-index.html","primary_entity_key":"0001404644","primary_entity_name":"Neurogene Inc."},"word_count":59,"has_tables":true,"body_markdown":"Item 8.01Other Events\n\nOn June 29, 2026, the Company also made publicly available a presentation announcing positive, updated clinical data from its Phase 1/2 trial evaluating NGN-401gene therapy for the treatment of females with Rett syndrome. A copy of the presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference."}